MX2013007527A - Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo. - Google Patents

Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo.

Info

Publication number
MX2013007527A
MX2013007527A MX2013007527A MX2013007527A MX2013007527A MX 2013007527 A MX2013007527 A MX 2013007527A MX 2013007527 A MX2013007527 A MX 2013007527A MX 2013007527 A MX2013007527 A MX 2013007527A MX 2013007527 A MX2013007527 A MX 2013007527A
Authority
MX
Mexico
Prior art keywords
hpv
monoclonal antibody
neutralizing antibody
measuring
protein
Prior art date
Application number
MX2013007527A
Other languages
English (en)
Inventor
Tadahito Kanda
Selichiro Mori
Original Assignee
Japan Health Science Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Science Found filed Critical Japan Health Science Found
Publication of MX2013007527A publication Critical patent/MX2013007527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente invención se refiere al desarrollo de un anticuerpo monoclonal que tiene actividad de unión a muchos tipos de alto riesgo de VPH, etc. La presente invención también proporciona un método simple y de alto rendimiento para la medición de los títulos de anticuerpos neutralizantes cruzados, que se utilizan para ensayo de anticuerpos neutralizantes cruzados contra el VPH en muestras de suero de individuos, etc. El método de la presente invención para medir los títulos de anticuerpos neutralizantes cruzados comprende las etapas de: preparar un anticuerpo monoclonal en contra de un péptido que tiene una secuencia de aminoácidos específica común a tipos de alto riesgo de VPH; y ensayo de anticuerpos neutralizantes cruzados usando este anticuerpo monoclonal.
MX2013007527A 2010-12-27 2011-12-26 Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo. MX2013007527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010291067 2010-12-27
PCT/JP2011/079994 WO2012090895A1 (ja) 2010-12-27 2011-12-26 ヒトパピローマウィルス（hpv）ｌ２蛋白質を認識するモノクローナル抗体とそれを使用したhpv中和抗体価測定法

Publications (1)

Publication Number Publication Date
MX2013007527A true MX2013007527A (es) 2014-02-27

Family

ID=46382999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007527A MX2013007527A (es) 2010-12-27 2011-12-26 Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo.

Country Status (14)

Country Link
US (2) US9279161B2 (es)
EP (1) EP2641914B1 (es)
JP (1) JP6106837B2 (es)
KR (1) KR101889119B1 (es)
CN (1) CN103582651A (es)
AU (1) AU2011350832A1 (es)
BR (1) BR112013016495A2 (es)
CA (1) CA2819947C (es)
MX (1) MX2013007527A (es)
NZ (1) NZ611168A (es)
RU (1) RU2013129203A (es)
SG (1) SG191125A1 (es)
TW (1) TW201233686A (es)
WO (1) WO2012090895A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3359190A4 (en) * 2015-10-05 2020-05-06 Circle33 LLC ANTIBODIES WITH IMPROVED STABILITY ABOUT DIGESTION
CN111417651B (zh) * 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
CN110196332A (zh) * 2019-05-22 2019-09-03 艾托金生物医药（苏州）有限公司 一种检测多亚型hpv e7蛋白的方法及其应用
CN112125972B (zh) * 2019-06-25 2022-07-29 神州细胞工程有限公司 抗hpv16 l1蛋白单克隆抗体及应用该抗体的检测方法
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法
KR20220155712A (ko) 2021-05-17 2022-11-24 (주)베데스다 인유두종 바이러스 및 자궁경부암 감지용 다클론성 항체 및 이의 제조방법
CN113444168B (zh) * 2021-06-23 2023-07-14 上海博唯生物科技有限公司 一种抗hpv35抗体及其制备方法和用途
CN115112885B (zh) * 2022-06-18 2023-07-28 杭州爱光健康科技有限公司 一种hpv检测试剂盒及其制备方法和应用
CN117143226B (zh) * 2023-09-12 2024-04-05 怡道生物科技(苏州)有限公司 与hpv33型衣壳蛋白l1特异性结合的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007358A (en) * 1931-11-27 1935-07-09 Edward W Anger Drainage valve
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH05227970A (ja) 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原
AU2008268014B2 (en) 2007-06-26 2013-10-31 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Also Published As

Publication number Publication date
TW201233686A (en) 2012-08-16
US20130337438A1 (en) 2013-12-19
WO2012090895A1 (ja) 2012-07-05
US9683997B2 (en) 2017-06-20
BR112013016495A2 (pt) 2018-05-22
EP2641914B1 (en) 2018-11-14
CA2819947C (en) 2020-03-24
US20160154007A1 (en) 2016-06-02
KR20140016875A (ko) 2014-02-10
EP2641914A9 (en) 2014-12-03
NZ611168A (en) 2015-03-27
JPWO2012090895A1 (ja) 2014-06-05
KR101889119B1 (ko) 2018-08-16
EP2641914A1 (en) 2013-09-25
US9279161B2 (en) 2016-03-08
JP6106837B2 (ja) 2017-04-05
SG191125A1 (en) 2013-07-31
CN103582651A (zh) 2014-02-12
AU2011350832A1 (en) 2013-06-20
EP2641914A4 (en) 2014-04-23
CA2819947A1 (en) 2012-07-05
RU2013129203A (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
MX2013007527A (es) Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo.
MX348071B (es) Variantes de fc.
WO2014080401A3 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
WO2011127412A3 (en) Soluble human st-2 antibodies and assays
JO3615B1 (ar) جسم مضاد كعامل نوعي تجاه الدايمر ألفا -4- بيتا-7-غير المتجانس
NZ701444A (en) Antibodies to matrix metalloproteinase 9
WO2013059524A3 (en) Antibodies directed against influenza
GB2490404B (en) Methods for determining ligand binding to a target protein using a thermal shift assay
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
MX2016005686A (es) Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
EP3103810A3 (en) Modified variable domain molecules and methods for producing and using them
NZ630920A (en) Antibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2011118982A3 (ko) 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법
EA201490286A1 (ru) Моноклональные антитела, специфичные в отношении x-37 бета-амилоида, и пути их применения
PL404498A1 (pl) Test diagnostyczny zakażeń Streptococcus agalactiae
WO2011089453A3 (en) Mass spectrometry-based protein identification
WO2013125936A3 (es) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino
TH179718A (th) แอนติบอดีของมนุษย์ต่อเรสไพราทอรีซินไซเทียลไวรัส f โปรตีน และวิธีการใช้ของมัน
WO2011153602A3 (pt) E-ntpdases recombinantes, uso na produção de kit de diagnósticos para detecção de anticorpos nas leishmanioses causadas por espécies do gênero leishmania
UA48956U (ru) Способ выявления специфических антител к возбудителю фузобактериоза (некробактериоза) методом иммуноферментного анализа в крови животных
UA104311C2 (ru) Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7

Legal Events

Date Code Title Description
FA Abandonment or withdrawal